Imunon, Inc. (IMNN)
NASDAQ: IMNN · IEX Real-Time Price · USD
1.310
-0.035 (-2.60%)
Apr 30, 2024, 3:56 PM EDT - Market closed
Imunon Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
12.31M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 500.00K | - | - |
Dec 31, 2021 | 500.00K | - | - |
Dec 31, 2020 | 500.00K | - | - |
Dec 31, 2019 | 500.00K | - | - |
Dec 31, 2018 | 500.00K | - | - |
Dec 31, 2017 | 500.00K | - | - |
Dec 31, 2016 | 500.00K | - | - |
Dec 31, 2015 | 500.00K | - | - |
Dec 31, 2014 | 500.00K | - | - |
Dec 31, 2013 | 500.00K | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 2.00M | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 2.50M | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 2.51M | - | - |
Sep 30, 2003 | 0 | - | - |
Sep 30, 2002 | 0 | - | - |
Sep 30, 2001 | 0 | - | - |
Sep 30, 2000 | 3.42K | - | - |
Sep 30, 1999 | 0 | - | - |
Sep 30, 1998 | 174.18K | 52.93K | 43.65% |
Sep 30, 1997 | 121.26K | 47.25K | 63.85% |
Sep 30, 1996 | 74.01K | -83.61K | -53.05% |
Sep 30, 1995 | 157.62K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CareMax | 751.10M |
Centogene | 55.72M |
Zhongchao | 17.23M |
Novo Integrated Sciences | 13.66M |
RedHill Biopharma | 6.53M |
NEXGEL | 4.09M |
Elevai Labs | 1.71M |
IMNN News
- 12 days ago - IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 - GlobeNewsWire
- 19 days ago - IMUNON Reports Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 weeks ago - IMUNON Reports 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses - GlobeNewsWire
- 5 weeks ago - IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 - GlobeNewsWire
- 6 weeks ago - IMUNON Files IND Application to Begin Human Testing of IMNN-101 - GlobeNewsWire
- 7 weeks ago - IMUNON Announces Leadership Change - GlobeNewsWire
- 2 months ago - Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 - GlobeNewsWire